SCHEMBL276922

SCHEMBL276922

NNC(=O)c1ccc(C(=O)NN2CCOCC2)s1

nearest known ligand 0.69

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
HTT P42858 2/20 0.69
SMN1; SMN2 Q16637 2/20 0.50
CYP2D6 P10635 1/20 0.50
HPGD P15428 1/20 0.49
KMT2A Q03164 4/20 0.47
LMNA P02545 1/20 0.47
MAPK1 P28482 1/20 0.47
ALDH1A1 P00352 5/20 0.43
MAPT P10636 3/20 0.43
KDM4E B2RXH2 2/20 0.43
POLB P06746 1/20 0.43
L3MBTL1 Q9Y468 2/20 0.43
MEN1 O00255 2/20 0.43
GAA P10253 1/20 0.41
LIPE Q05469 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL277005 0.84 HTT (0.50) HTTKMT2ALMNAMAPK1ALDH1A1
SCHEMBL12313815 0.82 HTT (0.66) HTTSMN1; SMN2CYP2D6HPGDKMT2A
SCHEMBL276182 0.82 HTT (0.66) HTTSMN1; SMN2CYP2D6HPGDKMT2A
SCHEMBL279600 0.82 HTT (0.69) HTTSMN1; SMN2CYP2D6HPGDKMT2A
SCHEMBL277360 0.82 KMT2A (0.69) HTTSMN1; SMN2CYP2D6KMT2ALMNA
SCHEMBL1587973 0.82 HPGD (0.76) HTTSMN1; SMN2HPGDKMT2AALDH1A1
SCHEMBL14395480 0.81 HTT (0.68) HTTSMN1; SMN2CYP2D6HPGDKMT2A
SCHEMBL12265883 0.78 HTT (0.64) HTTSMN1; SMN2CYP2D6HPGDKMT2A
SCHEMBL277558 0.77 MEN1 (0.64) HPGDKMT2ALMNAALDH1A1KDM4E
SCHEMBL276955 0.76 ALDH1A1 (0.58) CYP2D6KMT2ALMNAALDH1A1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8134013-B2 Amide compound and thrombopoietin receptor activator NISSAN CHEMICAL INDUSTRIES, LTD. (JP) 2012-03-13 US disclosed
US-8026368-B2 Hydrazide compounds and thrombopoietin receptor activators NISSAN CHEMICAL INDUSTRIES, LTD. (JP) 2011-09-27 US disclosed
US-8026368-B2 Hydrazide compounds and thrombopoietin receptor activators NISSAN CHEMICAL INDUSTRIES, LTD. (JP) 2011-09-27 US disclosed
US-20090253751-A1 HYDRAZIDE COMPOUND AND THROMBOPOIETIN RECEPTOR ACTIVATOR NISSAN CHEMICAL INDUSTRIES, LTD. (JP) 2009-10-08 US disclosed
US-20090253751-A1 HYDRAZIDE COMPOUND AND THROMBOPOIETIN RECEPTOR ACTIVATOR NISSAN CHEMICAL INDUSTRIES, LTD. (JP) 2009-10-08 US disclosed
US-20090131659-A1 AMIDE COMPOUND AND THROMBOPOIETIN RECEPTOR ACTIVATOR NISSAN CHEMICAL INDUSTRIES, LTD. (JP) 2009-05-21 US disclosed
EP-1947101-A1 HYDRAZIDE COMPOUND AND THROMBOPOIETIN RECEPTOR ACTIVATOR Nissan Chemical Industries, Ltd. (JP) 2008-07-23 EP disclosed
EP-1845090-A1 AMIDE COMPOUND AND THROMBOPOIETIN RECEPTOR ACTIVATOR Nissan Chemical Industries, Ltd. (JP) 2007-10-17 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090131659-A1 AMIDE COMPOUND AND THROMBOPOIETIN RECEPTOR ACTIVATOR TEK, PTAFR, MPL HTT 1630/4885SMN1; SMN2 1437/4885CYP2D6 2749/4885
US-20090253751-A1 HYDRAZIDE COMPOUND AND THROMBOPOIETIN RECEPTOR ACTIVATOR TEK, THPO, PTAFR HTT 160/4885SMN1; SMN2 1287/4885CYP2D6 1543/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.